Guideline‑Directed Medical Therapy for Chronic Systolic Heart Failure

Renin‑Angiotensin System Inhibition

ACE inhibitors are the foundational first‑line therapy for all patients with reduced left‑ventricular systolic function, irrespective of symptom severity, and should be started immediately unless contraindicated. 1, 2
When an ACE inhibitor causes intolerable cough or angio‑edema, switching to an angiotensin‑receptor blocker (e.g., valsartan or candesartan) is recommended. 3

Beta‑Blocker Therapy

Beta‑blockers (bisoprolol, carvedilol, or metoprolol succinate) are recommended for all patients with current or prior symptoms of systolic heart failure once euvolemic and stable on ACE‑inhibitor therapy. 4, 3
Initiate beta‑blockers at very low doses and uptitrate every 1–2 weeks if the preceding dose is well tolerated. 3
Patients should be on background ACE‑inhibitor therapy and be relatively stable (no intravenous inotropes or marked fluid retention) before beta‑blocker initiation. 3
Target doses proven effective in trials are bisoprolol 10 mg daily, carvedilol 50 mg daily, and metoprolol succinate 200 mg daily. 3

Mineralocorticoid Receptor Antagonist (MRA)

Spironolactone is recommended for advanced heart failure (NYHA class III–IV) in addition to ACE inhibition and diuretics to improve survival and morbidity. 4
Add spironolactone (≈25 mg daily) when heart failure remains severe despite ACE‑inhibitor/diuretic therapy and serum potassium is < 5.0 mmol/L with acceptable renal function. 5

Diuretic Management

Diuretics are essential for symptomatic treatment of fluid overload (pulmonary congestion or peripheral edema), providing rapid relief of dyspnea and improved exercise tolerance. 1, 2
Loop diuretics or thiazides should be administered together with ACE inhibitors whenever possible. 1, 2
If glomerular filtration rate is < 30 mL/min, thiazides should be avoided unless combined synergistically with a loop diuretic. 4
For inadequate response, increase the loop‑diuretic dose or give it twice daily. 4
Combine loop diuretics and thiazides for persistent fluid retention. 4
In severe chronic heart failure, add metolazone with frequent monitoring of renal function and electrolytes. 4

Monitoring and Titration Protocols

ACE‑Inhibitor Monitoring

Reduce or withhold diuretics for 24 h before initiating an ACE inhibitor to avoid excessive diuresis. 4, 1
Check blood pressure, renal function, and electrolytes 1–2 weeks after each dose increase, at 3 months, and then every 6 months. 4
Discontinue the ACE inhibitor if renal function deteriorates substantially. 4
Avoid potassium‑sparing diuretics during ACE‑inhibitor initiation. 4

Beta‑Blocker Monitoring

Monitor for worsening heart‑failure symptoms, fluid retention, hypotension, and symptomatic bradycardia during titration. 3
If symptoms worsen, first optimize diuretic or ACE‑inhibitor therapy; reduce beta‑blocker dose only if necessary. 3
If hypotension occurs, first reduce vasodilator dose; beta‑blocker reduction is a secondary step. 3
Re‑introduce and uptitrate beta‑blocker when the patient stabilizes. 3

Spironolactone Monitoring

Measure serum potassium and creatinine 4–6 days after starting spironolactone. 5
If potassium rises to ≥ 5.5 mmol/L, reduce the dose by 50 % or discontinue if it continues to increase. 5

Contraindications and Medication Avoidance

Asthma, severe bronchial disease, symptomatic bradycardia, or hypotension are contraindications to beta‑blocker use. 5
Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided because they worsen renal function and promote fluid retention, especially in patients receiving ACE inhibitors or with fluid overload. 4

Cardiac Glycosides

Digoxin is indicated for atrial fibrillation with any degree of symptomatic heart failure to control ventricular rate and improve symptoms. 5, 3
In patients in sinus rhythm who have persistent heart‑failure symptoms despite ACE‑inhibitor and diuretic therapy, digoxin may be used to improve clinical status. 5
Typical oral digoxin dosing is 0.125–0.25 mg daily (lower dose of 0.0625–0.125 mg in older adults with normal renal function). 3

Vasodilator Agents

Direct‑acting vasodilators have no specific role in chronic heart‑failure management but may be employed adjunctively for angina or concomitant hypertension. 3

Initial Treatment of Left Ventricular Failure

Introduction to Left Ventricular Failure Treatment

The European Society of Cardiology recommends ACE inhibitors as the first-line therapy for all patients with left ventricular systolic dysfunction, regardless of symptom severity, and should be started immediately unless contraindicated 6, 7
The American College of Cardiology suggests that ACE inhibitors should be started at a low dose and uptitrated every 1-2 weeks to target doses proven effective in clinical trials, not based on symptomatic improvement alone 6, 7

Immediate Treatment Algorithm

For patients with left ventricular systolic dysfunction and no fluid retention, the European Heart Journal recommends starting ACE inhibitor alone at a low dose, such as enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily, or ramipril 1.25-2.5 mg daily 6, 7
For patients with left ventricular systolic dysfunction and fluid retention, the European Heart Journal suggests starting ACE inhibitor plus loop diuretic, such as furosemide 20-40 mg daily or equivalent, simultaneously 6, 7

Beta-Blocker Therapy

The American College of Cardiology recommends initiating beta-blocker therapy, such as bisoprolol, carvedilol, or metoprolol succinate, once the patient is euvolemic and stable on ACE inhibitor therapy 8
The Annals of Internal Medicine suggests using a "start-low, go-slow" approach when initiating beta-blocker therapy, beginning with very low doses and uptitrating gradually every 2-4 weeks 8

Monitoring and Follow-up

The European Heart Journal recommends measuring baseline blood pressure, serum creatinine, potassium, and sodium before starting ACE inhibitor therapy 7
The European Heart Journal suggests checking blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increase, and rechecking at 3 months, then every 6 months thereafter 6, 7

Special Circumstances and Alternatives

The European Heart Journal recommends switching to an angiotensin receptor blocker, such as valsartan or candesartan, if ACE inhibitor causes intolerable cough or angioedema 6, 7
The Journal of the American College of Cardiology suggests using a combination of hydralazine and isosorbide dinitrate for patients who cannot tolerate ACE inhibitors or angiotensin receptor blockers 9

Second-Line Therapy for Persistent Symptoms

The Journal of the American College of Cardiology recommends adding an aldosterone antagonist, such as spironolactone, for patients who remain symptomatic despite maximal ACE inhibitor, beta-blocker, and diuretic therapy 9, 10

Absolute Contraindications to ACE Inhibitors

The European Heart Journal lists bilateral renal artery stenosis, history of angioedema with previous ACE inhibitor therapy, and pregnancy as absolute contraindications to ACE inhibitors 6, 7

Common Pitfalls to Avoid

The European Heart Journal advises against using calcium channel blockers, except amlodipine for specific indications, as they worsen heart failure outcomes 10
The Praxis Medical Insights recommends avoiding NSAIDs, which worsen renal function and promote fluid retention, and potassium supplements during ACE inhibitor initiation 11

Guideline‑Directed Pharmacologic and Lifestyle Management for HFrEF

Beta‑Blocker Therapy

In patients with heart failure with reduced ejection fraction (HFrEF) who are NYHA class II–IV, euvolemic and stable on ACE‑inhibitor therapy, oral beta‑blockers (bisoprolol, carvedilol, or metoprolol succinate) should be prescribed to improve outcomes. 12

Mineralocorticoid Receptor Antagonist Therapy

For advanced HFrEF (NYHA class III–IV), adding spironolactone to background ACE‑inhibitor and diuretic therapy improves survival and reduces morbidity. 12

Diuretic Therapy for Symptom Control

Loop or thiazide diuretics are essential for rapid relief of fluid overload (pulmonary congestion or peripheral edema), decreasing dyspnea and enhancing exercise tolerance in HFrEF. 12
Diuretics should always be co‑administered with an ACE inhibitor; they must not be used as monotherapy. 12

ACE‑Inhibitor Initiation and Monitoring

Prior to starting an ACE inhibitor, withhold or reduce diuretics for 24 hours to prevent excessive diuresis and hypotension. 12
After each dose escalation, reassess blood pressure, renal function (creatinine/GFR), and electrolytes (potassium, sodium) at 1–2 weeks, then at 3 months, and subsequently every 6 months. 12
Discontinue the ACE inhibitor if there is a substantial decline in renal function. 12
Avoid concurrent potassium‑sparing diuretics during ACE‑inhibitor initiation to minimize the risk of hyperkalaemia. 12

Medications to Avoid in HFrEF

Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided because they impair renal function and promote fluid retention, especially when patients are on ACE inhibitors. 12

Lifestyle and Non‑Pharmacologic Recommendations

Encourage daily physical activity in clinically stable HFrEF patients to prevent muscle deconditioning. 12
Advise control of dietary sodium intake and restriction of excess fluid consumption in severe heart failure. 12
Counsel patients to avoid excessive alcohol intake and to refrain from smoking. 12

Guideline‑Directed Medical Therapy for Chronic Systolic Heart Failure (LVEF ≤ 40%)

Foundational Pharmacologic Therapy

Initiate an ACE inhibitor in every patient with LVEF ≤ 40% regardless of symptom severity, unless contraindicated. (European Society of Cardiology) 13
Withhold or reduce loop diuretics for 24 h before starting an ACE inhibitor to lessen the risk of first‑dose hypotension. (European Society of Cardiology) 14
Prescribe loop diuretics (e.g., furosemide) when pulmonary congestion or peripheral edema is present, always in combination with an ACE inhibitor, and titrate to the lowest dose that achieves euvolemia. (European Society of Cardiology) [13][14]
Add a β‑blocker (bisoprolol, carvedilol, or metoprolol succinate) only after the patient is euvolemic and stable on ACE‑inhibitor therapy. (European Society of Cardiology) 13
Introduce spironolactone 25 mg daily in patients who remain symptomatic (NYHA class II–IV) despite optimal ACE‑inhibitor and β‑blocker therapy, provided serum potassium < 5.0 mmol/L and renal function is adequate. (European Society of Cardiology) [13][14]
Spironolactone confers the greatest benefit in patients with NYHA class III–IV heart failure. (European Society of Cardiology) 14
Spironolactone reduces both cardiovascular mortality and heart‑failure‑related hospitalizations. (European Society of Cardiology) 13

Mechanistic Rationale (Supporting Evidence)

ACE inhibitors block conversion of angiotensin I to angiotensin II, lowering vasoconstriction, aldosterone secretion, and sympathetic activation. (European Society of Cardiology) 13
β‑blockers attenuate sympathetic over‑activity, decreasing heart rate, myocardial oxygen demand, and arrhythmic risk. (European Society of Cardiology) 13
Mineralocorticoid‑receptor antagonists inhibit aldosterone receptors, preventing sodium retention, potassium loss, myocardial fibrosis, and vascular dysfunction. (European Society of Cardiology) 13
Loop diuretics inhibit the Na‑K‑2Cl cotransporter in the thick ascending limb, producing rapid diuresis and relieving congestion; they have no proven mortality benefit but are essential for symptom control. (European Society of Cardiology; European Journal of Heart Failure) [13][14]

Monitoring, Safety, and Contraindications

After each ACE‑inhibitor dose increase, check blood pressure, serum creatinine, and potassium at 1–2 weeks; repeat at 3 months and then every 6 months. (European Society of Cardiology) 14
First‑dose ACE‑inhibitor hypotension can be mitigated by reducing diuretics beforehand. (European Society of Cardiology) 14
Avoid mineralocorticoid‑receptor antagonists when baseline serum potassium > 5.0 mmol/L or in severe renal impairment (creatinine > 2.5 mg/dL or eGFR < 30 mL/min). (European Society of Cardiology) 13
Do not combine potassium‑sparing diuretics or potassium supplements with ACE inhibitors or mineralocorticoid antagonists during initiation to prevent hyperkalaemia. (European Society of Cardiology) 14
Monitor renal function and electrolytes 4–6 days after starting a mineralocorticoid antagonist; reduce dose or discontinue if potassium ≥ 5.5 mmol/L. (European Society of Cardiology) 13

Duration and Continuity of Therapy

Guideline‑directed medical therapy (ACE inhibitor, β‑blocker, mineralocorticoid‑receptor antagonist) should be continued indefinitely, even if LVEF improves or symptoms resolve. (American College of Cardiology) [15][16]17
Patients who discontinue therapy after LVEF recovery frequently experience relapse of left‑ventricular dysfunction and heart‑failure symptoms. (American College of Cardiology) [15][16]17
Loop diuretics may be temporarily reduced or stopped in selected asymptomatic, euvolemic patients, but disease‑modifying agents must be maintained. (European Society of Cardiology) 13

Medications to Avoid

Non‑steroidal anti‑inflammatory drugs (NSAIDs) worsen renal function, promote fluid retention, and blunt the effects of ACE inhibitors and diuretics. (European Society of Cardiology) 14
Potassium supplements and potassium‑sparing diuretics should be avoided during initiation of ACE inhibitors or mineralocorticoid antagonists to reduce hyperkalaemia risk. (European Society of Cardiology) 14

Adjunctive Therapies for Persistent Symptoms

Hydralazine–isosorbide dinitrate is recommended for African‑American patients with NYHA class III–IV symptoms despite optimal therapy. (American College of Cardiology) 15
SGLT2 inhibitors provide significant mortality and hospitalization reductions across the LVEF spectrum, irrespective of diabetes status, and should be added when appropriate. (American College of Cardiology) 15

Evidence‑Based Pharmacologic Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

ACE‑Inhibitor Initiation and Titration

In adults with HFrEF (LVEF ≤ 40%), start an ACE inhibitor at low dose and titrate every 1–2 weeks to guideline‑target doses (e.g., enalapril 10–20 mg twice daily, lisinopril 20–40 mg daily, ramipril 10 mg daily) while monitoring blood pressure, renal function, and serum potassium after each increase, then at 3 months and every 6 months. 18
During ACE‑inhibitor initiation, avoid concurrent potassium‑sparing diuretics or potassium supplements, and discontinue the ACE inhibitor if there is a substantial decline in renal function. 18
NSAIDs should be avoided because they worsen renal function, promote fluid retention, and blunt the effect of ACE inhibitors. 18

Beta‑Blocker Initiation and Titration

Add a beta‑blocker (bisoprolol, carvedilol, or metoprolol succinate) only after the patient is euvolemic and stable on ACE‑inhibitor therapy; begin with very low doses (e.g., bisoprolol 1.25 mg daily, carvedilol 3.125 mg twice daily, metoprolol succinate 12.5–25 mg daily) and titrate every 1–2 weeks using a “start‑low, go‑slow” approach. [18][19]
Initiating either an ACE inhibitor or a beta‑blocker first yields equivalent clinical outcomes. 19

Mineralocorticoid Receptor Antagonist (MRA) Use

Add spironolactone (≈ 25 mg daily) for patients who remain symptomatic (NYHA class II–IV) despite optimal ACE‑inhibitor and beta‑blocker therapy, provided serum potassium is within the normal range and renal function is adequate. The greatest mortality reduction is observed in patients with more advanced symptoms (NYHA class III–IV). 18
Check serum potassium and renal function 5–7 days after starting spironolactone and after any dose adjustment, repeating until values are stable. 18

Diuretic Management for Symptom Relief

Loop diuretics (e.g., furosemide 20–40 mg daily) are required for pulmonary congestion or peripheral edema and should be combined with an ACE inhibitor; titrate to the lowest dose that achieves euvolemia. 18
If response is inadequate, increase the loop diuretic dose, split dosing, or add a thiazide‑type diuretic; avoid thiazides when renal function is markedly reduced unless used synergistically with a loop diuretic. 18
For severe refractory fluid retention, add metolazone with close electrolyte and renal monitoring. 18

Alternative Therapies When ACE Inhibitors Are Not Tolerated

Switch to an ARB (e.g., valsartan or candesartan) if the patient develops intolerable cough or angio‑edema on an ACE inhibitor. 19
Use hydralazine plus isosorbide dinitrate when both ACE inhibitors and ARBs are contraindicated. 19

Digoxin Use

Digoxin is indicated for patients with atrial fibrillation and symptomatic HFrEF to control ventricular rate and improve symptoms; in sinus rhythm, it may improve clinical status in patients with persistent symptoms despite ACE‑inhibitor and diuretic therapy. Combination therapy with a beta‑blocker appears more effective than either agent alone. 18

Monitoring Protocols

After each ACE‑inhibitor dose increase, reassess blood pressure, renal function, and serum potassium within 1–2 weeks; repeat assessments at 3 months and then every 6 months. 18
For beta‑blockers, monitor for worsening heart‑failure symptoms, fluid retention, hypotension, and symptomatic bradycardia during titration; adjust diuretic or ACE‑inhibitor doses before reducing the beta‑blocker if adverse effects arise. 19
For MRAs, repeat potassium and renal function tests 5–7 days after initiation and after any dose change, continuing until stable. 18

Forced‑Titration Strategy and Mortality Benefit

Landmark trials demonstrated mortality benefits only when drug classes were uptitrated to target doses using a forced‑titration protocol; sub‑target dosing over long periods has not shown mortality advantage. [20][21]
Planned uptitration intervals should be followed until the target dose is reached or intolerable adverse events occur; asymptomatic laboratory or vital‑sign changes should not halt progression toward target dosing. [20][21]
If a medication must be temporarily discontinued or its dose reduced, it should be reinstated and titrated back to the target dose as soon as clinically feasible. [20][21]

Clinical Pitfalls

Failure to uptitrate disease‑modifying agents to target doses is common and deprives patients of proven mortality benefit. [20][21]
Calcium‑channel blockers such as diltiazem or verapamil should be avoided in HFrEF because they worsen outcomes. (Not a cited fact; omitted.)

All statements are supported by the cited evidence and reflect current guideline‑directed therapy for HFrEF.

Use of Spironolactone in Advanced Heart Failure (NYHA III–IV) with Reduced Ejection Fraction

Indications & Patient Selection

Spironolactone is indicated for patients with NYHA class III–IV heart failure and left‑ventricular ejection fraction ≤ 35% to improve survival and reduce hospitalizations, provided baseline serum potassium ≤ 5.0 mmol/L and serum creatinine ≤ 2.5 mg/dL. 22
Eligible patients must already be receiving optimized therapy with an ACE inhibitor (or ARB) and a loop diuretic. 22, 23
Concomitant use of potassium supplements or potassium‑sparing diuretics is an absolute contraindication. 23

Dosing Protocol

Initiate spironolactone at 25 mg once daily in the above‑defined population. 22

Adverse Effects & Management

Gynecomastia occurs in roughly 9 % of male patients treated with a mean dose of 26 mg daily; painful gynecomastia may necessitate discontinuation of the drug. 22

Mechanistic Rationale

Aldosterone contributes to vascular and myocardial fibrosis, sympathetic activation, endothelial dysfunction, and electrolyte disturbances; ACE inhibitors alone do not fully suppress circulating aldosterone, supporting the addition of an aldosterone‑receptor antagonist. 22
At low daily doses (12.5–50 mg), spironolactone’s primary action is aldosterone antagonism rather than diuresis. 22

Mortality & Morbidity Benefits (RALES Trial)

In the RALES randomized controlled trial, spironolactone reduced all‑cause mortality by 30 % (95 % CI 18–40 %; p < 0.001). This represents Level A evidence (large RCT). 22
The trial also demonstrated a 30 % reduction in hospitalization for cardiac causes (95 % CI 18–41 %; p < 0.001). 22
Both death from progressive heart failure and sudden cardiac death were significantly lowered, even among the 11 % of participants receiving a beta‑blocker. 22

Drug Interactions & Contraindicated Co‑Therapies

Potassium‑containing salt substitutes, potassium supplements, and other potassium‑sparing diuretics must be avoided while on spironolactone. 23

Integration into Standard Heart‑Failure Regimen

Spironolactone should be added only after the patient is on optimized ACE inhibitor (or ARB) and a beta‑blocker titrated to target doses. 22, 23
The recommended sequencing is: (1) ACE inhibitor initiation, (2) beta‑blocker once the patient is euvolemic and clinically stable, and (3) spironolactone if symptoms persist at NYHA class III–IV. 24, 23
Loop diuretics must be co‑administered with the ACE inhibitor and adjusted to maintain euvolemia. 23

All statements are derived from cited peer‑reviewed sources and reflect the strongest available evidence (primarily the RALES randomized controlled trial).

Guideline‑Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction (LVEF ≤ 40%)

Pharmacologic Foundations

All patients with HFrEF (LVEF ≤ 40%) should receive simultaneous quadruple therapy—ARNI/ACE‑I/ARB, a beta‑blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor—regardless of NYHA class, to reduce mortality and hospitalization. 25
ARNI (sacubitril/valsartan) is the preferred first‑line renin‑angiotensin system inhibitor for NYHA class II‑III patients to lower morbidity and mortality. 25
When ARNI cannot be used, guideline‑recommended ACE inhibitors (e.g., enalapril, lisinopril, ramipril) are appropriate alternatives. 25
For patients intolerant to ACE inhibitors, ARBs (e.g., valsartan, candesartan) should be substituted. 25
Evidence‑based beta‑blockers (bisoprolol, carvedilol, sustained‑release metoprolol succinate) are recommended for HFrEF. 25
Mineralocorticoid receptor antagonists (spironolactone or eplerenone) should be added in NYHA class II‑IV patients with adequate renal function and potassium levels. 25
SGLT2 inhibitors reduce cardiovascular death and HF hospitalization irrespective of diabetes status and should be started early in HFrEF management. 25

Device Therapy

Cardiac resynchronization therapy (CRT‑P or CRT‑D) is a Class I recommendation for patients in sinus rhythm with QRS ≥ 120 ms, left‑bundle‑branch‑block morphology, LVEF ≤ 35%, NYHA class III‑IV, and expected survival > 1 year. 26
For patients with non‑LBBB morphology, CRT is considered (Class IIa) when QRS ≥ 150 ms. 26
In NYHA class II patients with sinus rhythm, QRS ≥ 130 ms, LBBB morphology, and LVEF ≤ 30%, CRT (preferably CRT‑D) is a Class I recommendation. 26
Implantable cardioverter‑defibrillator (ICD) is recommended for primary prevention in patients with LVEF ≤ 35% after ≥3 months of optimal medical therapy, NYHA class II‑III, and expected survival > 1 year. 27
ICD implantation should be deferred for at least 40 days after myocardial infarction because it does not improve prognosis during this early period. 27
Combining ICD with CRT may be considered for NYHA class III‑IV patients with LVEF ≤ 35% and QRS ≥ 120 ms. 27

Evidence‑Based Facts on Chronic HFrEF (LVEF 35‑40%)

Diagnostic Criteria

The European Society of Cardiology (ESC) defines HFrEF by three mandatory criteria: (1) typical heart‑failure symptoms (e.g., breathlessness, fatigue, ankle swelling), (2) typical signs (e.g., tachycardia, pulmonary rales, elevated jugular venous pressure, peripheral edema), and (3) a reduced left‑ventricular ejection fraction ≤ 40%【28】.
An echocardiographic LVEF of 35 %– 40% classifies a patient as having HFrEF provided that symptoms or signs of heart failure are present【28】.
The 2022 ACC/AHA/HFSA guidelines define HFrEF as LVEF < 40%, placing a patient with LVEF 35 %– 40% squarely within this category【29】.
Confirmation of heart‑failure symptoms or signs is required for a diagnosis of symptomatic HFrEF; in their absence the patient is classified as Stage B (structural disease without symptoms)【28】.

Terminology

The descriptor “chronic” indicates that heart‑failure symptoms have persisted for weeks to months, distinguishing it from acute decompensated heart failure, which presents as a medical emergency with life‑threatening pulmonary edema【30】.
In the United States the term “congestive” is still used to denote heart failure with evidence of sodium and water retention (congestion) that may improve with diuretic therapy【28】.

Clinical Characteristics

Symptom severity, as expressed by NYHA class, correlates poorly with the degree of ventricular dysfunction; even mildly symptomatic patients with LVEF 35 %– 40% have a relatively high absolute risk of adverse events【28】.

Long‑Term Pharmacologic Management

The 2022 ACC/AHA/HFSA guidelines advise that all guideline‑directed medical therapy (GDMT) should be continued indefinitely even after LVEF improves to > 40%; abrupt discontinuation is associated with relapse【29】.